Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

By S. Faivre, C. Delbaldo, K. Vera, C. Robert, Stéphanie Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini and 3 more. Journal of Clinical Oncology, 2006

1,165 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/92cd6c95fa81c7720540b97785ca77b2591da570

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Adamis
2. R. Roskoski
3. N. Ferrara
4. Rakesh K. Jain
5. Peter Carmeliet
6. R. Apte
7. Daniel Chen
8. H. Gerber

In Pathology and Forensic Medicine

1. R. Roskoski

In Pulmonary and Respiratory Medicine

1. N. Ferrara
2. R. Roskoski

Citations in the corpus

• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011, neutral): “Abdominal pain 23 (28) 19 (23) 4 (5) 26 (32) 18 (22) 8 (10)”
• Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “Hypertension also occurred in people treated with SU1248 (sunitinib) [283] and BAY 43-9006 (sorafenib) [284], mall molecule drugs that inhibit VEGF receptors and other rotein kinases.”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…in the MARINA and ANCHOR trials 207 , 208 , resulting in FDA approval for neovascular AMD • Sunitinib demonstrates anti-tumour activity as a second-line therapy in a Phase II trial on metastatic renal carcinoma 19,116,271 and in Phase I–III clinical trials for gastrointestinal stromal tumour 21 .”